250 related articles for article (PubMed ID: 30458450)
1. 6- and 8-Prenylnaringenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma Cells.
Venturelli S; Niessner H; Sinnberg T; Berger A; Burkard M; Urmann C; Donaubauer K; Böcker A; Leischner C; Riepl H; Frank J; Lauer UM; Garbe C; Busch C
Cell Physiol Biochem; 2018; 51(2):543-556. PubMed ID: 30458450
[TBL] [Abstract][Full Text] [Related]
2. Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases.
Berger A; Venturelli S; Kallnischkies M; Böcker A; Busch C; Weiland T; Noor S; Leischner C; Weiss TS; Lauer UM; Bischoff SC; Bitzer M
J Nutr Biochem; 2013 Jun; 24(6):977-85. PubMed ID: 23159065
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells.
Venturelli S; Berger A; Böcker A; Busch C; Weiland T; Noor S; Leischner C; Schleicher S; Mayer M; Weiss TS; Bischoff SC; Lauer UM; Bitzer M
PLoS One; 2013; 8(8):e73097. PubMed ID: 24023672
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity.
Munshi A; Kurland JF; Nishikawa T; Tanaka T; Hobbs ML; Tucker SL; Ismail S; Stevens C; Meyn RE
Clin Cancer Res; 2005 Jul; 11(13):4912-22. PubMed ID: 16000590
[TBL] [Abstract][Full Text] [Related]
5. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.
Krumm A; Barckhausen C; Kücük P; Tomaszowski KH; Loquai C; Fahrer J; Krämer OH; Kaina B; Roos WP
Cancer Res; 2016 May; 76(10):3067-77. PubMed ID: 26980768
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and characterization of α, β-unsaturated carboxylic acid, and its urea based derivatives that explores novel epigenetic modulators in human non-small cell lung cancer A549 cell line.
Chidambaram A; Sundararaju K; Chidambaram RK; Subbiah R; Jayaraj JM; Muthusamy K; Vilwanathan R
J Cell Physiol; 2018 Jul; 233(7):5293-5309. PubMed ID: 29215703
[TBL] [Abstract][Full Text] [Related]
8. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
Mazzio EA; Soliman KFA
Cancer Genomics Proteomics; 2018; 15(5):349-364. PubMed ID: 30194076
[TBL] [Abstract][Full Text] [Related]
9. Anti-proliferative activity of hop-derived prenylflavonoids against human cancer cell lines.
Busch C; Noor S; Leischner C; Burkard M; Lauer UM; Venturelli S
Wien Med Wochenschr; 2015 Jun; 165(11-12):258-61. PubMed ID: 25925225
[TBL] [Abstract][Full Text] [Related]
10. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, characterization, and evaluation of Cd[L-proline]
Chidambaram A; Sekar A; S H K; Chidambaram RK; Arunachalam K; G P S; Vilwanathan R
Invest New Drugs; 2017 Dec; 35(6):691-705. PubMed ID: 28776290
[TBL] [Abstract][Full Text] [Related]
12. Influence of side-chain changes on histone deacetylase inhibitory and cytotoxicity activities of curcuminoid derivatives.
Somsakeesit LO; Senawong T; Kumboonma P; Saenglee S; Samankul A; Senawong G; Yenjai C; Phaosiri C
Bioorg Med Chem Lett; 2020 Jun; 30(11):127171. PubMed ID: 32273215
[TBL] [Abstract][Full Text] [Related]
13. Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.
Liu ZH; Li J; Xia J; Jiang R; Zuo GW; Li XP; Chen Y; Xiong W; Chen DL
Chem Biol Interact; 2015 Dec; 242():227-34. PubMed ID: 26482938
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors reduce WB-F344 oval cell viability and migration capability by suppressing AKT/mTOR signaling in vitro.
Zhang P; Zhu X; Wu Y; Hu R; Li D; Du J; Jiao X; He X
Arch Biochem Biophys; 2016 Jan; 590():1-9. PubMed ID: 26558695
[TBL] [Abstract][Full Text] [Related]
15. Development of novel ferulic acid derivatives as potent histone deacetylase inhibitors.
Wang F; Lu W; Zhang T; Dong J; Gao H; Li P; Wang S; Zhang J
Bioorg Med Chem; 2013 Nov; 21(22):6973-80. PubMed ID: 24095016
[TBL] [Abstract][Full Text] [Related]
16. The Oral Bioavailability of 8-Prenylnaringenin from Hops (Humulus Lupulus L.) in Healthy Women and Men is Significantly Higher than that of its Positional Isomer 6-Prenylnaringenin in a Randomized Crossover Trial.
Calvo-Castro LA; Burkard M; Sus N; Scheubeck G; Leischner C; Lauer UM; Bosy-Westphal A; Hund V; Busch C; Venturelli S; Frank J
Mol Nutr Food Res; 2018 Apr; 62(7):e1700838. PubMed ID: 29363261
[TBL] [Abstract][Full Text] [Related]
17. A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.
Yang L; Liang Q; Shen K; Ma L; An N; Deng W; Fei Z; Liu J
Biomed Pharmacother; 2015 Apr; 71():70-8. PubMed ID: 25960218
[TBL] [Abstract][Full Text] [Related]
18. Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.
Cho M; Choi E; Yang JS; Lee C; Seo JJ; Kim BS; Oh SJ; Kim HM; Lee K; Park SK; Kwon HJ; Han G
ChemMedChem; 2013 Feb; 8(2):272-9. PubMed ID: 23292995
[TBL] [Abstract][Full Text] [Related]
19. Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells.
Makarević J; Tawanaie N; Juengel E; Reiter M; Mani J; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
J Cell Mol Med; 2014 Jul; 18(7):1460-6. PubMed ID: 24779401
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
